CXCR4 expression and treatment with SDF-1α or plerixafor modulate proliferation and chemosensitivity of colon cancer cells

Translational Oncology

Volumn 6, Issue 2, 2013, Pages 124-132

  Heckmann, Doreen ^a,b   Maier, Patrick ^c   Laufs, Stephanie ^a   Wenz, Frederik ^c   Zeller, W Jens ^a   Fruehauf, Stefan ^d   Allgayer, Heike ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Paracelsus Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CHEMOKINE RECEPTOR CXCR4; FLUOROURACIL; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA;

APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84875785031     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12268     Document Type: Article

References (48)

1. Compton CC (2003). Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 16, 376-388.
2. Becouarn Y, Senesse P, Thezenas S, Boucher E, Adenis A, Cany L, Jacob JH, Cvitkovic F, Montoto-Grillot C, and Ychou M (2007). A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 18, 2000-2005.
3. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, et al. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25, 4779-4786.
4. Zlotnik A (2008). New insights on the role of CXCR4 in cancer metastasis. J Pathol 215, 211-213.
5. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, and Hoon DS (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23, 2744-2753.
6. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V, Junginger T, Berger MR, Galle PR, and Moehler M (2005). Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 11, 1743-1750.
7. Aiuti A, Webb IJ, Bleul C, Springer T, and Gutierrez-Ramos JC (1997). The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185, 111-120.
8. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
9. Ben-Baruch A (2008). Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 25, 345-356.
10. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, and Ratajczak MZ (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894.
11. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
12. Orimo A and Weinberg RA (2006). Stromal fibroblasts in cancer: a novel tumorpromoting cell type. Cell Cycle 5, 1597-1601.
13. Pinto MP, Badtke MM, Dudevoir ML, Harrell JC, Jacobsen BM, and Horwitz KB (2010). Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptorpositive breast cancer. Cancer Res 70, 2655-2664.
14. Patel SA, Dave MA, Murthy RG, Helmy KY, and Rameshwar P (2011). Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev 5, 93-102.
15. Pantel K and Brakenhoff RH (2004). Dissecting the metastatic cascade. Nat Rev Cancer 4, 448-456.
16. Chambers AF, Groom AC, and MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572.
17. Riethmuller G and Klein CA (2001). Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 11, 307-311.
18. Burger JA and Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767.
19. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, Jackson JB, Coombs RW, Glesby MJ, Flexner CW, et al. (2004). Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37, 1253-1262.
20. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, and Henson GW (2000). Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44, 1667-1673.
21. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, et al. (2003). Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102, 2728-2730.
22. Burger JA and Peled A (2009). CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43-52.
23. Heckmann D, Laufs S, Maier P, Zucknick M, Giordano FA, Veldwijk MR, Eckstein V, Wenz F, Zeller WJ, Fruehauf S, et al. (2011). A lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals Plerixafor-dependent suppression of SDF-1α-induced migration and invasion. Onkologie 34, 502-508.
24. De Clercq E (2009). The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77, 1655-1664.
25. Breems DA, Blokland EA, and Ploemacher RE (1997). Stroma-conditioned media improve expansion of human primitive hematopoietic stem cells and progenitor cells. Leukemia 11, 142-150.
26. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, and Thrasher AJ (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13, 803-813.
27. Mudduluru G, Vajkoczy P, and Allgayer H (2010). Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 8, 159-169.
28. Maier P, Spier I, Laufs S, Veldwijk MR, Fruehauf S, Wenz F, and Zeller WJ (2010). Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K. Gene Ther 17, 389-399.
29. Chou TC and Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55.
30. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller WJ, and Fruehauf S (2009). Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. Leuk Lymphoma 50, 1676-1686.
31. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang YM, Qin SX, Newman W, and Groopman JE (1998). The α-chemokine, stromal cell-derived factor-1α, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 273, 23169-23175.
32. Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte JM, Goke B, and Eichhorst ST (2005). CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 310, 117-130.
33. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, and Heveker N (2009). AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75, 1240-1247.
34. Bhowmick NA, Neilson EG, and Moses HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337.
35. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, and Dalton WS (1999). Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667.
36. Li ZW and Dalton WS (2006). Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20, 333-342.
37. Essers MA and Trumpp A (2010). Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 4, 443-450.
38. Balkwill F (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14, 171-179.
39. Wang L, Li CL, Yu WB, Yin HP, Zhang GY, Zhang LF, Li S, and Hu SY (2011). Influence of CXCR4/SDF-1 axis on E-cadherin/β-catenin complex expression in HT29 colon cancer cells. World J Gastroenterol 17, 625-632.
40. Zeelenberg IS, Ruuls-Van SL, and Roos E (2003). The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63, 3833-3839.
41. Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK, and Menger MD (2007). Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 9, 862-870.
42. Gassmann P, Haier J, Schluter K, Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider SW, Homey B, et al. (2009). CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia 11, 651-661.
43. Rollins BJ (1997). Chemokines. Blood 90, 909-928.
44. Lapidot T and Kollet O (2002). The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2mnull mice. Leukemia 16, 1992-2003.
45. Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, Dierks C, Pfeifer D, Ott A, Mertelsmann R, et al. (2010). The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 151, 167-178.
46. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al. (2009). CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351.
47. Pattarozzi A, Gatti M, Barbieri F, Wurth R, Porcile C, Lunardi G, Ratto A, Favoni R, Bajetto A, Ferrari A, et al. (2008). 17β-Estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 73, 191-202.
48. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, and Bardelli A (2005). Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6, 279-286.